Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by N0taP00pon Mar 10, 2023 3:32pm
648 Views
Post# 35331518

Plausible scenarios

Plausible scenarios Let's say the fast-track driven access to the FDA has given enough confidence to TLT  that BTD is almost a given. Where would you spend your time and effort next?  I would like to think it is in designing a trial that meets FDA guidelines for an AA.  Maybe 4 treatments over one year and then monitor for 1 year after the last treatment, putting the AA grant timeline in the 2025 timeframe.  Those 9 extra centers would be busy if they got BTD. Also, hoping that BTD allows them to collect some revenue till full approval granted.  In the best case scenario they get BTD and AA together.  Very long odds though.  


In parallel, or maybe next, is preparing a trial to use TLD-1433 before BCG ie. under the Frontrunner program.  This assumes the FDA also sees the potential for this PDC to be tried pre-BCG and indicated as much to TLT. The FDA needs to start using that Frontrunner program at some point. Given the safety profile and CR data, TLD-1433 seems to fit. IMHO. 

Both of these options need $$. The options to raise money would be much much broader if they could get BTD first.   VC, JV, Nasdaq listing, etc.  If I see an attempt to raise money before BTD, my take is that they are scraping the bottom of their piggy bank already and have no clear indication of getting BTD yet, maybe because they're still collecting data for a more sureshot submission.  

One can speculate. 
<< Previous
Bullboard Posts
Next >>